In our initial investigation, preliminary characterization of PLC-associated microbiota across histopathological variants and clinical prognoses uncovered microbiome disparities that distinguished: 1 tumor from adjacent non-tumor tissue, 2 different histological subtypes, and 3 patients with divergent clinical outcomes (Qu et al., 2022). This evidence concerns the gene HSPG2 and neoplasm.